Drug Trials Snapshot: CIBINQO

CIBINQO is a Janus Kinase (JAK) inhibitor that is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Source: FDA Center for Drug Evaluation and Research - What's New - June 7, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news